Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fampridine crossover study in multiple sclerosis with internuclear ophthalmoplegia
2015-000182-31Phase 2Completed
- Sponsor
- Centre for Human Drug Research
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dalfampridine in multiple sclerosis (MS) (2 arms), sponsored by Centre for Human Drug Research. Primary endpoint: Effects of fampridine on eye movements. Started Jan 2015; status: completed.
02
Drugs
dalfampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2015-000182-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000182-31.